NewAmsterdam Pharma (NAMS) Accounts Payables (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Accounts Payables of $8.1 million for Q1 2026, down 9.81% sequentially from $9.0 million in Q4 2025, and up 32.91% YoY from $6.1 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Accounts Payables (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Accounts Payables for 6 years, with the latest figure at $8.1 million in Q1 2026.
- Quarterly Accounts Payables rose 32.91% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (up 32.91% YoY) and the FY2025 annual result came in at $9.0 million, up 89.08% from the prior year.
- Accounts Payables fell to $8.1 million in Q1 2026 per NAMS's latest filing, from $9.0 million in the prior quarter.
- Over five years, Accounts Payables peaked at $22.7 million in Q2 2023 and troughed at $3.6 million in Q3 2025.
- A 5-year average of $9.7 million and a median of $7.6 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables tumbled 76.77% in 2024, then surged 89.08% in 2025.
- Over 5 years, Accounts Payables stood at $18.9 million in 2022, then fell by 10.35% to $16.9 million in 2023, then sank by 71.97% to $4.7 million in 2024, then soared by 89.08% to $9.0 million in 2025, then decreased by 9.81% to $8.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $8.1 million, $9.0 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 5.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.42 Mn |
| Mar 31, 2026 | 8.09 Mn |
| Dec 31, 2025 | 8.97 Mn |
| Sep 30, 2025 | 3.63 Mn |
| Jun 30, 2025 | 5.90 Mn |
| Mar 31, 2025 | 6.09 Mn |
| Dec 31, 2024 | 4.74 Mn |
| Sep 30, 2024 | 7.04 Mn |
| Jun 30, 2024 | 5.28 Mn |
| Mar 31, 2024 | 8.54 Mn |
| Dec 31, 2023 | 16.92 Mn |
| Jun 30, 2023 | 22.71 Mn |
| Dec 31, 2022 | 18.88 Mn |
| Dec 31, 2021 | 11.24 Mn |